Authors:
- Comprehensively explores the biology and role of MDSCs in cancer
- Covers therapeutic targeting via the STAT3 pathway, a major regulatory pathway in MDSCs functions as well as in tumour cells
- Particularly relevant for scientists working in the pharmaceutical industry and in oncology research
- Includes supplementary material: sn.pub/extras
Part of the book series: SpringerBriefs in Immunology (BRIEFSIMMUN)
Buy it now
Buying options
Tax calculation will be finalised at checkout
Other ways to access
This is a preview of subscription content, log in via an institution to check for access.
Table of contents (7 chapters)
-
Front Matter
About this book
Authors and Affiliations
-
Fundación Miguel Servet, IdiSNA, Navarrabiomed-Biomedical Research Centre, Pamplona, Spain
David Escors, Grazyna Kochan
-
Dept. of Pathology and Microbiology, University of Nebraska Medical Center, OMAHA, USA
James E. Talmadge
-
Faculty of Medicine and Pharmacy, Vrije Universiteit Brussel, Brussel, Belgium
Karine Breckpot
-
VIB Lab Myeloid Cell Immun, BLDG. E, Vrije Universiteit Brussel, Brussels, Belgium
Jo A. Van Ginderachter
Bibliographic Information
Book Title: Myeloid-Derived Suppressor Cells and Cancer
Authors: David Escors, James E. Talmadge, Karine Breckpot, Jo A. Van Ginderachter, Grazyna Kochan
Series Title: SpringerBriefs in Immunology
DOI: https://doi.org/10.1007/978-3-319-26821-7
Publisher: Springer Cham
eBook Packages: Biomedical and Life Sciences, Biomedical and Life Sciences (R0)
Copyright Information: The Author(s) 2016
Softcover ISBN: 978-3-319-26819-4Published: 23 March 2016
eBook ISBN: 978-3-319-26821-7Published: 15 March 2016
Series ISSN: 2194-2773
Series E-ISSN: 2194-2781
Edition Number: 1
Number of Pages: IX, 102
Number of Illustrations: 8 illustrations in colour
Topics: Immunology, Cancer Research, Oncology, Cell Biology